OVERVIEW
The first results of three anti-HER2 strategies that incorporated lapatinib and trastuzumab and compared these with trastuzumab alone as adjuvant therapy for patients with HER2-positive early breast cancer.
STUDY DETAILS
The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial is the first large prospective randomised trial to report three anti-HER2 strategies that incorporated lapatinib and trastuzumab and compared these with trastuzumab alone as adjuvant therapy for patients with early-stage HER2-positive breast cancer.
Title of Publication
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
AUTHORS
Piccart-Gebhart, M., Holmes, E., Baselga, J., De Azambuja, E., Dueck, A.C., Viale, G., Zujewski, J.A., Goldhirsch, A., Armour, A., Pritchard, K.I., McCullough, A.E., Dolci, S., McFadden, E., Holmes, A.P., Tonghua, L., Eidtmann, H., Dinh, P., Di Cosimo, S., Harbeck, N., Tjulandin, S., Im, Y-H., Huang, C-S., Diéras, V., Hillman, D.W., Wolff, A.C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Suter, T., Gelber, R.D., and Perez, E.A.
Publication Reference
Journal of Clinical Oncology (JCO) | Volume 34 | Issue 10 | Page(s) 1034-1042 | 2016
